BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng Y, Deng L, Ding Y, Chen Q, Wu Y, Yang M, Wang Y, Fu Q. Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation. PLoS One 2014;9:e89932. [PMID: 24587133 DOI: 10.1371/journal.pone.0089932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Qin J, Xiong K, Jiang B, Zhang T. Review of arginase as a promising biocatalyst: characteristics, preparation, applications and future challenges. Crit Rev Biotechnol 2021;:1-17. [PMID: 34612104 DOI: 10.1080/07388551.2021.1947962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pérez DJ, Ávila-rodríguez MA. Methods to radiolabel somatostatin analogs with [18F]fluoride: current status, challenges, and progress in clinical applications. J Radioanal Nucl Chem 2020;326:1519-1542. [DOI: 10.1007/s10967-020-07437-6] [Reference Citation Analysis]
3 Streuli J, Harris AG, Cottiny C, Allagnat F, Daly AF, Grouzmann E, Abid K. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides 2018;68:84-9. [PMID: 29523357 DOI: 10.1016/j.npep.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wan A, Xu D, Liu K, Peng L, Cai Y, Chen Y, He Y, Yang J, Jin J, Li H. Efficient expression of stable recombinant human insulin-like growth factor-1 fusion with human serum albumin in Chinese hamster ovary cells. Prep Biochem Biotechnol 2017;47:678-86. [PMID: 28281882 DOI: 10.1080/10826068.2017.1303612] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Caspersen MB, Kuhlmann M, Nicholls K, Saxton MJ, Andersen B, Bunting K, Cameron J, Howard KA. Albumin-based drug delivery using cysteine 34 chemical conjugates – important considerations and requirements. Therapeutic Delivery 2017;8:511-9. [DOI: 10.4155/tde-2017-0038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
6 Wan A, Miao Y, Peng L, Cai Y, Chen Y, He Y, Yang J, Jin J, Li H. Binding and biologic characterization of recombinant human serum albumin-eTGFBR2 fusion protein expressed in CHO cells. Bioengineered 2017;8:600-12. [PMID: 28281868 DOI: 10.1080/21655979.2017.1292186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
7 Xu D, Wan A, Zhang J, Peng L, Chen Y, He Y, Yang J, Jin J. Inhibition of the ubiquitin ligase activity improves the production of biologically active fusion protein HSA-HGF in Chinese hamster ovary cells. Bioengineered 2017;8:256-64. [PMID: 27753513 DOI: 10.1080/21655979.2016.1227898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Strohl WR. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs 2015;29:215-39. [PMID: 26177629 DOI: 10.1007/s40259-015-0133-6] [Cited by in Crossref: 248] [Cited by in F6Publishing: 213] [Article Influence: 41.3] [Reference Citation Analysis]